Latest & greatest articles for sepsis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sepsis

161. A Multicenter Randomized Trial of Continuous versus Intermittent beta-Lactam Infusion in Severe Sepsis

A Multicenter Randomized Trial of Continuous versus Intermittent beta-Lactam Infusion in Severe Sepsis 26200166 2015 12 02 2016 04 04 2017 03 14 1535-4970 192 11 2015 12 01 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. 1298-305 10.1164/rccm.201505-0857OC Continuous infusion of β-lactam antibiotics may improve outcomes because of time-dependent (...) antibacterial activity compared with intermittent dosing. To evaluate the efficacy of continuous versus intermittent infusion in patients with severe sepsis. We conducted a randomized controlled trial in 25 intensive care units (ICUs). Participants commenced on piperacillin-tazobactam, ticarcillin-clavulanate, or meropenem were randomized to receive the prescribed antibiotic via continuous or 30-minute intermittent infusion for the remainder of the treatment course or until ICU discharge. The primary

EvidenceUpdates2015

162. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study

Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2014

163. Association Between the Choice of IV Crystalloid and In-Hospital Mortality Among Critically Ill Adults With Sepsis

Association Between the Choice of IV Crystalloid and In-Hospital Mortality Among Critically Ill Adults With Sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2014

164. Impact of sepsis on risk of postoperative arterial and venous thromboses: large prospective cohort study.

Impact of sepsis on risk of postoperative arterial and venous thromboses: large prospective cohort study. OBJECTIVES: To evaluate the impact of preoperative sepsis on risk of postoperative arterial and venous thromboses. DESIGN: Prospective cohort study using the National Surgical Quality Improvement Program database of the American College of Surgeons (ACS-NSQIP). SETTING: Inpatient and outpatient procedures in 374 hospitals of all types across the United States, 2005-12. PARTICIPANTS (...) : 2,305,380 adults who underwent surgical procedures. MAIN OUTCOME MEASURES: Arterial thrombosis (myocardial infarction or stroke) and venous thrombosis (deep venous thrombosis or pulmonary embolism) in the 30 days after surgery. RESULTS: Among all surgical procedures, patients with preoperative systemic inflammatory response syndrome or any sepsis had three times the odds of having an arterial or venous postoperative thrombosis (odds ratio 3.1, 95% confidence interval 3.0 to 3.1). The adjusted odds

BMJ2014 Full Text: Link to full Text with Trip Pro

165. Treatment With Neuromuscular Blocking Agents and the Risk of In-Hospital Mortality Among Mechanically Ventilated Patients With Severe Sepsis

Treatment With Neuromuscular Blocking Agents and the Risk of In-Hospital Mortality Among Mechanically Ventilated Patients With Severe Sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2014

166. The Sepsis in Obstetrics Score: a model to identify risk of morbidity from sepsis in pregnancy

The Sepsis in Obstetrics Score: a model to identify risk of morbidity from sepsis in pregnancy 24613756 2014 06 28 2014 08 25 2014 06 28 1097-6868 211 1 2014 Jul American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. The Sepsis in Obstetrics Score: a model to identify risk of morbidity from sepsis in pregnancy. 39.e1-8 10.1016/j.ajog.2014.03.010 S0002-9378(14)00215-4 We sought to design an emergency department sepsis scoring system to identify risk of intensive care unit (ICU (...) ) admission in pregnant and postpartum women. The Sepsis in Obstetrics Score (S.O.S.) was created by modifying validated scoring systems in accordance with recognized physiologic changes of pregnancy. The S.O.S. was applied to a retrospective cohort of pregnant and postpartum patients from February 2009 through May 2011 with clinical suspicion of sepsis. The primary outcome was ICU admission. Secondary outcomes were telemetry unit admission, length of stay, positive blood cultures, positive influenza

EvidenceUpdates2014

167. Rosuvastatin for sepsis-associated acute respiratory distress syndrome.

Rosuvastatin for sepsis-associated acute respiratory distress syndrome. BACKGROUND: In the acute respiratory distress syndrome (ARDS), inflammation in the lungs and other organs can cause life-threatening organ failure. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) can modulate inflammatory responses. Previous observational studies suggested that statins improved clinical outcomes in patients with sepsis. We hypothesized that rosuvastatin therapy would improve clinical (...) outcomes in critically ill patients with sepsis-associated ARDS. METHODS: We conducted a multicenter trial in which patients with sepsis-associated ARDS were randomly assigned to receive either enteral rosuvastatin or placebo in a double-blind manner. The primary outcome was mortality before hospital discharge home or until study day 60 if the patient was still in a health care facility. Secondary outcomes included the number of ventilator-free days (days that patients were alive and breathing

NEJM2014

168. Can Procalcitonin Differentiate Sepsis From Systemic Inflammatory Response Syndrome Without Infection?

Can Procalcitonin Differentiate Sepsis From Systemic Inflammatory Response Syndrome Without Infection? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2014

169. Functional outcomes in pediatric severe sepsis: further analysis of the researching severe sepsis and organ dysfunction in children: a global perspective trial

Functional outcomes in pediatric severe sepsis: further analysis of the researching severe sepsis and organ dysfunction in children: a global perspective trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2014

170. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2014

171. Albumin replacement in patients with severe sepsis or septic shock.

Albumin replacement in patients with severe sepsis or septic shock. BACKGROUND: Although previous studies have suggested the potential advantages of albumin administration in patients with severe sepsis, its efficacy has not been fully established. METHODS: In this multicenter, open-label trial, we randomly assigned 1818 patients with severe sepsis, in 100 intensive care units (ICUs), to receive either 20% albumin and crystalloid solution or crystalloid solution alone. In the albumin group (...) (relative risk, 0.94; 95% CI, 0.85 to 1.05; P=0.29). No significant differences in other secondary outcomes were observed between the two groups. CONCLUSIONS: In patients with severe sepsis, albumin replacement in addition to crystalloids, as compared with crystalloids alone, did not improve the rate of survival at 28 and 90 days. (Funded by the Italian Medicines Agency; ALBIOS ClinicalTrials.gov number, NCT00707122 .).

NEJM2014

172. A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2014

173. Stratification of risk of early-onset sepsis in newborns >/= 34 weeks` gestation

Stratification of risk of early-onset sepsis in newborns >/= 34 weeks` gestation 24366992 2014 01 03 2014 02 24 2016 10 19 1098-4275 133 1 2014 Jan Pediatrics Pediatrics Stratification of risk of early-onset sepsis in newborns ≥ 34 weeks' gestation. 30-6 10.1542/peds.2013-1689 To define a quantitative stratification algorithm for the risk of early-onset sepsis (EOS) in newborns ≥ 34 weeks' gestation. We conducted a retrospective nested case-control study that used split validation. Data (...) collected on each infant included sepsis risk at birth based on objective maternal factors, demographics, specific clinical milestones, and vital signs during the first 24 hours after birth. Using a combination of recursive partitioning and logistic regression, we developed a risk classification scheme for EOS on the derivation dataset. This scheme was then applied to the validation dataset. Using a base population of 608,014 live births ≥ 34 weeks' gestation at 14 hospitals between 1993 and 2007, we

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

174. Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012.

Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012. IMPORTANCE: Severe sepsis and septic shock are major causes of mortality in intensive care unit (ICU) patients. It is unknown whether progress has been made in decreasing their mortality rate. OBJECTIVE: To describe changes in mortality for severe sepsis with and without shock in ICU patients. DESIGN, SETTING, AND PARTICIPANTS: Retrospective, observational study from 2000 (...) to 2012 including 101,064 patients with severe sepsis from 171 ICUs with various patient case mix in Australia and New Zealand. MAIN OUTCOMES AND MEASURES: Hospital outcome (mortality and discharge to home, to other hospital, or to rehabilitation). RESULTS: Absolute mortality in severe sepsis decreased from 35.0% (95% CI, 33.2%-36.8%; 949/2708) to 18.4% (95% CI, 17.8%-19.0%; 2300/12,512; P < .001), representing an overall decrease of 16.7% (95% CI, 14.8%-18.6%), an annual rate of absolute decrease

JAMA2014

175. Splenectomy and the Risk of Sepsis: A Population-Based Cohort Study

Splenectomy and the Risk of Sepsis: A Population-Based Cohort Study 24374533 2014 11 12 2015 01 09 2014 11 12 1528-1140 260 6 2014 Dec Annals of surgery Ann. Surg. Splenectomy and the risk of sepsis: a population-based cohort study. 1081-7 10.1097/SLA.0000000000000439 We sought to estimate the long-term risk of sepsis in patients who underwent splenectomy before, during, and after implementation of vaccination. Because patients who have undergone splenectomy are considered at increased risk (...) of bacterial sepsis, they typically receive vaccination, education, and occasionally antibiotic prophylaxis. However, the extent to which these interventions have actually reduced the risk of sepsis remains unclear. Retrospective cohort study encompassing all patients in the Swedish national inpatient register, who underwent splenectomy in 1970-2009. Patients were followed for hospitalization for or death from sepsis, as identified using national inpatient and cause of death registers. Relative risks

EvidenceUpdates2014

176. Boceprevir (Victrelis) and telaprevir (Incivo): predictive factors for sepsis, worsening liver function, and mortality

Boceprevir (Victrelis) and telaprevir (Incivo): predictive factors for sepsis, worsening liver function, and mortality Boceprevir (Victrelis) and telaprevir (Incivo): predictive factors for sepsis, worsening liver function, and mortality Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Boceprevir (Victrelis) and telaprevir (Incivo): predictive factors for sepsis, worsening liver function, and mortality From: Published: 17 November 2014 Therapeutic area (...) : and A European review identified baseline markers as predictive factors for morbidity requiring hospitalisation and mortality in cirrhotic patients. Article date: November 2014 A European review identified the following baseline markers as predictive factors for morbidity requiring hospitalisation (eg, sepsis, worsening liver function) and mortality in cirrhotic patients treated with either boceprevir or telaprevir in combination with peginterferon alfa and ribavirin: low platelet count hypoalbuminaemia

MHRA Drug Safety Update2014

177. Biomarkers (e.g. Procalcitonin) to Diagnose Sepsis in the ED

Biomarkers (e.g. Procalcitonin) to Diagnose Sepsis in the ED Emergency Medicine > Journal Club > Archive > March 2014 Toggle navigation March 2014 Biomarkers (e.g.Procalcitonin) to Diagnose Sepsis in the ED Vignette You are rotating at a hospital just outside of Honolulu, HI. A patient presents from dialysis with nausea and vomiting. The patient has been feeling unwell for several days, presented to dialysis and had several episodes of non-­‐bloody emesis. Their dialysis session was completed (...) of infection. Intervention: Use of procalcitonin to identify patients with bacterial sepsis Comparison: Standard management Outcome: Diagnosis of sepsis due to bacterial infection Search Strategy You access PubMed and search the Clinical Queries tool using the terms "procalcitonin AND sepsis" with the narrow filter applied ( ). This results in 261 articles, from which you choose the following four, including recent meta-­‐analysis on the topic. Articles Article 1: Article 2: Article 3: Article 4: Bottom

Washington University Emergency Medicine Journal Club2014

178. Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome.

Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome. 24835849 2014 06 06 2014 06 10 2016 12 28 1533-4406 370 23 2014 Jun 05 The New England journal of medicine N. Engl. J. Med. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. 2191-200 10.1056/NEJMoa1401520 In the acute respiratory distress syndrome (ARDS), inflammation in the lungs and other organs can cause life-threatening organ failure. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (...) (statins) can modulate inflammatory responses. Previous observational studies suggested that statins improved clinical outcomes in patients with sepsis. We hypothesized that rosuvastatin therapy would improve clinical outcomes in critically ill patients with sepsis-associated ARDS. We conducted a multicenter trial in which patients with sepsis-associated ARDS were randomly assigned to receive either enteral rosuvastatin or placebo in a double-blind manner. The primary outcome was mortality before

NEJM2014 Full Text: Link to full Text with Trip Pro

179. Albumin Replacement in Patients with Severe Sepsis or Septic Shock.

Albumin Replacement in Patients with Severe Sepsis or Septic Shock. 24635772 2014 04 10 2014 04 18 2015 03 20 1533-4406 370 15 2014 Apr 10 The New England journal of medicine N. Engl. J. Med. Albumin replacement in patients with severe sepsis or septic shock. 1412-21 10.1056/NEJMoa1305727 Although previous studies have suggested the potential advantages of albumin administration in patients with severe sepsis, its efficacy has not been fully established. In this multicenter, open-label trial (...) , we randomly assigned 1818 patients with severe sepsis, in 100 intensive care units (ICUs), to receive either 20% albumin and crystalloid solution or crystalloid solution alone. In the albumin group, the target serum albumin concentration was 30 g per liter or more until discharge from the ICU or 28 days after randomization. The primary outcome was death from any cause at 28 days. Secondary outcomes were death from any cause at 90 days, the number of patients with organ dysfunction and the degree

NEJM2014

180. Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock

Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock Hohn A, Schroeder S, Gehrt A, Bernhardt K, Bein B, Wegscheider K, Hochreiter M Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the impact of an algorithm, based on procalcitonin, to reduce the length of antibiotic therapy, for adults with severe sepsis and septic shock, in a surgical intensive care unit. The authors concluded that the algorithm decreased

NHS Economic Evaluation Database.2013